Recent studies have shown that rituximab, a B-cell-depleting anti-CD20 monoclonal antibody and mepolizumab, an anti-IL-5-antibody also induce remission in EGPA [16], [17], [18]. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.